A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
- Robert S. DiPaola
- , Yu Hui Chen
- , Mark Stein
- , David Vaughn
- , Linda Patrick-Miller
- , Michael Carducci
- , Bruce Roth
- , Eileen White
- , George Wilding
Research output: Contribution to journal › Article › peer-review
16
Scopus
citations